Treatment withdrawal · people who smoke
It is very uncertain whether combination changes treatment withdrawals compared with single‐form nicotine replacement therapy (very low certainty).
1 finding from 1 review
Smoking cessation ‐ 16 weeks versus 8 weeks · people who smoke
It is very uncertain whether longer changes smoking cessation ‐ 16 weeks versus 8 weeks compared with shorter duration of combination nicotine replacement therapy (very low certainty).
1 finding from 1 review
Smoking cessation · people who smoke
Longer showed no clear difference in smoking cessation ‐ 6 weeks versus 2 weeks compared with shorter duration of combination nicotine replacement therapy (low certainty).
1 finding from 1 review
SAEs · people who smoke
It is very uncertain whether longer changes overall SAEs ‐ 26 weeks versus 8 weeks compared with shorter duration of combination nicotine replacement therapy (very low certainty).
3 findings from 1 review
RR 1.63 [0.6, 4.42]
1 study · 544 participants
Very low
no estimate extracted
1 study · 637 participants
Very low
no estimate extracted
1 study · 987 participants
Very low
Treatment withdrawal · people who smoke
1 finding from 1 review
Overall survival · people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
Platinum doublet probably leads to lower overall survival compared with non‐platinum therapy (moderate certainty).
1 finding from 1 review
12‐month survival rates · people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
Platinum doublet probably leads to lower 12‐month survival rates compared with non‐platinum therapy (moderate certainty).
1 finding from 1 review
Progression‐free survival · people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
Platinum doublet probably leads to lower progression‐free survival compared with non‐platinum therapy (moderate certainty).
1 finding from 1 review
Tumor response rate · people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
Platinum doublet probably leads to higher tumor response rate compared with non‐platinum therapy (moderate certainty).
1 finding from 1 review
Toxicity – anemia grade 3–5 · people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
Platinum doublet showed no clear difference in toxicity – anemia grade 3–5 compared with non‐platinum therapy (low certainty).
1 finding from 1 review
Toxicity – neutropenia grade 3–5 · people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
Platinum doublet may leads to higher toxicity – neutropenia grade 3–5 compared with non‐platinum therapy (low certainty).
1 finding from 1 review
Toxicity – thrombocytopenia grade 3–5 · people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
Platinum doublet may leads to higher toxicity – thrombocytopenia grade 3–5 compared with non‐platinum therapy (low certainty).
1 finding from 1 review
Fatigue · adults with breast or prostate cancer receiving radiation therapy alone
1 finding from 1 review
QoL · adults with breast or prostate cancer receiving radiation therapy alone
1 finding from 1 review
Physical performance · adults with breast or prostate cancer receiving radiation therapy alone
1 finding from 1 review
Psychosocial effects Measured at 5‐8 weeks (short term); end scores. Positive SMD values signify better psychosocial effects. · adults with breast or prostate cancer receiving radiation therapy alone
1 finding from 1 review
Overall survival · adults with breast or prostate cancer receiving radiation therapy alone
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Return to work · adults with breast or prostate cancer receiving radiation therapy alone
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults with breast or prostate cancer receiving radiation therapy alone
1 finding from 1 review
Time to death from any cause Range of · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors showed no clear difference in time to death from any cause Range of compared with any first‐line chemotherapy (moderate certainty).
1 finding from 1 review